By Ram Aiyar, CEO of Korro Bio, as part of the From The Trenches feature of LifeSciVC Let me tell you a secret that most biotech executives won’t admit at cocktail parties: we’re all making it up as we go

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC Building the right team is a popular topic because it is difficult and a company’s success hinges on it. In a cash-crunched biotech

By Ankit Mahadevia, founder and board director of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Biotech leaders love talking about ‘margin of safety’—but what if the safety nets we build are just illusions? In The Intelligent

By Cody Tranbarger, EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC As the biotech industry trudges through its fourth consecutive year of middling performance and sluggish capital markets, corporate governance has become a salient

By Gerry Harriman, CSO and co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC As scientists, we are accustomed to learning something new about targets (and the modulation thereof) that moves the field forward in

By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC If you are a first-time founder who has heard the phrase “This isn’t a good time to be raising for X,” where X

By Jason Campagna, CMO of Q32, as part of the From The Trenches feature of LifeSciVC In a recent essay, I argued that biotech is entering its strategic infrastructure moment, a shift from molecule-centric innovation to a layered capability stack

By Ram Aiyar, CEO of Korro Bio, as part of the From The Trenches feature of LifeSciVC It has been an extraordinary journey so far and one that continues to humble, inspire and motivate me every day. I’ve had the

By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC It’s easy to jump on the ‘negative bandwagon’ these days when news in our world and industry is focused on doom & gloom.

Over 200 GLP1 obesity programs are in development today.  More than 300 PD1/PDL1 cancer programs exist.  Greater than 150 programs target each of CD19 and KRAS. Therapeutic crowding has ratcheted up the competitive intensity in biotech to new levels. While

By Ankit Mahadevia, former CEO of Spero Therapeutics and Atlas alumni, as part of the From The Trenches of LifeSciVC I recently read Yuval Noah Hariri’s Nexus; what stuck with me was how a society uses information to create shared

By Cody Tranbarger, EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC It’s an interesting time to be thinking about space. Just a few months ago, SpaceX captivated and inspired the world by catching a